Please assess the completion status of the following clinical trial:

Trial Title: Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women greater than or equal to 18 years of age;~* A mean baseline platelet count between:~  * 50 × 10\^9/L and \<100 × 10\^9/L for non-chronic liver disease participants~ * 50 × 10\^9/L and \<75 × 10\^9/L for participants with chronic liver disease;~* Participant is scheduled to undergo operations to critical sites (eg, eye surgery, neurosurgery) or operations with a high risk of bleeding (eg, major abdominal surgery), or, in the opinion of the Investigator, would otherwise require a pre-operative platelet transfusion to prevent bleeding~Exclusion Criteria:~* Participant with a history of arterial or venous thrombosis within 6 months of baseline;~* Participant with known portal vein blood flow velocity rate \<10 cm/second or previous portal vein thrombosis within 6 months of baseline;~* Participant plans to have a platelet transfusion or plans to receive blood products containing platelets within 7 days of the Baseline Visit;~* Use of erythropoietin-stimulating agents;~* Participant has a known medical history of genetic prothrombotic syndromes; or~* Participant has abnormal hemoglobin levels or prothrombin time/international normalized ratio

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avatrombopag 60 mg (Type: EXPERIMENTAL): Open-label: oral avatrombopag

Based on this trial design, predict the completion outcome and termination type (if applicable).